HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
Vactosertib in Osteosarcoma
This study is now recruiting.
This study involves a taking a study drug called vactosertib by mouth. The overall goal of this study is to find out if vactosertib is a safe and effective treatment for adolescents and adults with recurrent, refractory or progressive Osteosarcoma.
Who Do I Contact?
If you are interested in participating in the study or want to learn more please contact our study team at CancerTrials [at] chop.edu or 267-425-5544.
Eligibility & Criteria
IRB #:
22-020384
Official Title:
A Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib as a Single Agent in Adolescents and Adults
Study Phase:
Phase I
Phase II
Eligible Age Range:
14 - 24 Years
Gender:
All